State Street
COGT icon

State Street’s Cogent Biosciences COGT Stock Holding History

State Street’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270M Buy
6,964,919
+1,301,376
+23% +$45.5M 0.01% 876
2026
Q1 		$218M Buy
5,663,543
+723,243
+15% +$26.7M 0.01% 894
2025
Q4 		$175M Buy
4,940,300
+164,881
+3% +$4.64M 0.01% 1016
2025
Q3 		$68.6M Buy
4,775,419
+1,403,507
+42% +$16.6M ﹤0.01% 1567
2025
Q2 		$24.2M Sell
3,371,912
-744,884
-18% -$4.13M ﹤0.01% 2083
2025
Q1 		$24.7M Buy
4,116,796
+198,666
+5% +$1.56M ﹤0.01% 2008
2024
Q4 		$30.6M Buy
3,918,130
+686,668
+21% +$6.84M ﹤0.01% 1973
2024
Q3 		$34.9M Sell
3,231,462
-605,500
-16% -$5.9M ﹤0.01% 1881
2024
Q2 		$32.3M Sell
3,836,962
-3,789,907
-50% -$28.7M ﹤0.01% 1888
2024
Q1 		$51.3M Buy
7,626,869
+3,476,254
+84% +$21.5M ﹤0.01% 1716
2023
Q4 		$24.4M Buy
4,150,615
+1,182,980
+40% +$9.07M ﹤0.01% 2100
2023
Q3 		$28.9M Sell
2,967,635
-160,468
-5% -$1.9M ﹤0.01% 1938
2023
Q2 		$37M Sell
3,128,103
-299,611
-9% -$3.44M ﹤0.01% 1853
2023
Q1 		$37M Sell
3,427,714
-833,667
-20% -$10.7M ﹤0.01% 1841
2022
Q4 		$49.3M Buy
4,261,381
+852,779
+25% +$10.6M ﹤0.01% 1651
2022
Q3 		$50.9M Buy
3,408,602
+2,714,447
+391% +$37.2M ﹤0.01% 1588
2022
Q2 		$6.26M Buy
694,155
+68,523
+11% +$468K ﹤0.01% 2982
2022
Q1 		$4.69M Buy
625,632
+27,624
+5% +$192K ﹤0.01% 3212
2021
Q4 		$5.13M Buy
598,008
+14,993
+3% +$130K ﹤0.01% 3231
2021
Q3 		$4.9M Buy
583,015
+76,158
+15% +$584K ﹤0.01% 3249
2021
Q2 		$4.11M Buy
506,857
+486,657
+2,409% +$4.11M ﹤0.01% 3339
2021
Q1 		$177K Hold
20,200
– – ﹤0.01% 3858
2020
Q4 		$227K Buy
+20,200
New +$222K ﹤0.01% 3739
2019
Q2 		– Sell
-53,865
Closed -$946K – 3825
2019
Q1 		$946K Buy
53,865
+10,826
+25% +$185K ﹤0.01% 3348
2018
Q4 		$757K Buy
43,039
+26,079
+154% +$772K ﹤0.01% 3378
2018
Q3 		$699K Buy
16,960
+11,185
+194% +$630K ﹤0.01% 3444
2018
Q2 		$331K Buy
+5,775
New +$278K ﹤0.01% 3516

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's COGT Position: Q2 2026 in Review

State Street increased its Cogent Biosciences (COGT) stake by 23% in Q2 2026, buying an estimated $45.5M and bringing the position to 6,964,919 shares worth $270M. The position accounts for 0.01% of the portfolio, ranked #876.

State Street first reported a position in COGT in Q2 2018 and has held it in 27 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • State Street held 6,964,919 shares of Cogent Biosciences worth $270M as of Q2 2026.
  • State Street bought 1,301,376 Cogent Biosciences shares in Q2 2026, an estimated $45.5M.
  • Cogent Biosciences made up 0.01% of State Street's portfolio in Q2 2026, its #876 holding.
  • State Street first reported a position in Cogent Biosciences in Q2 2018 and has held it in 27 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.